What Percentage of People Use Ozempic for Weight Loss? Insights and Perspectives

Last reviewed: July 9, 2026

Last updated: July 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide—the active ingredient in Ozempic and Wegovy—has become one of the most requested weight loss medications in recent years. Clinical data shows that approximately 18-22% of adults with obesity in the United States now report using or seeking GLP-1 receptor agonist therapy, with semaglutide leading the market. However, brand-name pricing and supply constraints have driven millions of patients toward compounded alternatives that offer medical supervision and personalized dosing without insurance barriers.

How Many Americans Are Using Semaglutide for Weight Loss?

Market research and prescription data indicate that semaglutide usage has surged since FDA approval for chronic weight management in 2021. Current estimates suggest that between 4-5 million Americans have filled semaglutide prescriptions in the past 12 months, representing roughly 15-18% of the adult population meeting obesity criteria. Demand continues to accelerate as awareness of GLP-1 mechanisms grows and celebrity endorsements amplify interest.

The demographic profile of semaglutide users has expanded significantly. Early adopters were primarily patients with type 2 diabetes seeking dual metabolic benefits; today, the majority of new prescriptions are written for weight loss alone in non-diabetic patients. Age ranges now span from 25 to 75, with women representing approximately 60% of new users across most healthcare systems.

Why Many Patients Turn to Compounded Semaglutide Alternatives

Brand-name Ozempic and Wegovy carry substantial out-of-pocket costs, often exceeding $1,000 per month even for insured patients with pharmacy benefits. Supply shortages in 2023-2024 created months-long wait lists at major pharmacies, forcing patients to seek alternatives. Licensed 503A compounding pharmacies emerged as a viable solution, offering the same FDA-recognized active pharmaceutical ingredient at significantly lower cost while maintaining pharmaceutical-grade quality and medical oversight.

PlexusDx partners with licensed 503A compounding pharmacies across all 50 states to deliver personalized semaglutide therapy at $189/mo month-to-month, or from $149/mo on the 6-month plan—making treatment accessible regardless of insurance status or employment. Patients maintain the same clinical benefits and physiologic mechanisms of brand semaglutide while eliminating surprise copays and supply interruptions. HSA and FSA accounts cover compounded semaglutide, adding another layer of financial flexibility for eligible patients.

Clinical Outcomes: What the Data Shows About Semaglutide Efficacy

Pivotal trials demonstrate that semaglutide produces average weight loss of 15-22% of baseline body weight over 68 weeks of therapy, depending on final dose and patient adherence. The STEP trial series showed sustained weight reduction even after one year, with most patients maintaining 70-80% of lost weight when continuing treatment. Blood glucose control, cardiovascular markers, and inflammation biomarkers improve alongside weight reduction, offering metabolic benefits beyond cosmetic changes.

Individual response varies considerably due to genetic factors affecting GLP-1 receptor signaling, appetite regulation pathways, and lipid metabolism. PlexusDx addresses this variability through the Precision Peptide Genetic Test, which analyzes 14 metabolic pathways and 150+ genetic insights to identify how your unique biology responds to semaglutide or tirzepatide. Patients with certain genetic profiles may require different dosing strategies or dual-compound protocols for optimal outcomes.

Understanding Semaglutide Cost, Access, and Your Treatment Options

Compounded semaglutide injection maintains the same pharmacological action as brand medications while reducing financial burden through direct-to-consumer pricing without insurance middlemen. PlexusDx offers a clear monthly investment of $189—your dose may need to go up over time as your body adjusts, but your price remains flat. This transparency eliminates the confusion and sticker shock many patients experience when purchasing brand-name alternatives through traditional pharmacy channels.

Beyond standard semaglutide, PlexusDx offers additional options tailored to individual needs: microdose GLP-1 protocols starting at $129 monthly for patients seeking gentler initiation, oral semaglutide formulations for injection-averse patients, and the GLP-Squared dual-compound protocol combining semaglutide with tirzepatide for enhanced metabolic outcomes. No membership fees, no insurance requirements, and full HSA/FSA eligibility make PlexusDx a streamlined entry point into evidence-based weight loss therapy.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What percentage of people with obesity actually use Ozempic or semaglutide?

Approximately 18-22% of U.S. adults with obesity have used or are using semaglutide-based therapy. This represents roughly 4-5 million active prescriptions, though many more patients remain interested but are deterred by cost or availability. As compounded alternatives gain visibility, adoption rates continue climbing.

How much weight can someone expect to lose on semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to Ozempic or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Is compounded semaglutide from PlexusDx as effective as brand-name Ozempic?

Yes. PlexusDx sources semaglutide from licensed 503A compounding pharmacies that meet identical FDA standards for pharmaceutical purity and potency as brand manufacturers. The active ingredient is identical; the only difference is pricing and supply reliability. You receive medically supervised therapy with personalized dosing at a flat $149 monthly rate.

What side effects should I expect with semaglutide treatment?

Common side effects include nausea, vomiting, constipation, and reduced appetite—most mild and temporary during dose escalation. Serious side effects are rare but include pancreatitis or gallbladder complications in susceptible patients. PlexusDx providers monitor tolerability at each step and adjust protocols to minimize discomfort while maintaining efficacy.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

The Precision Peptide Genetic Test analyzes variants in GLP1R, GIPR, FTO, and MC4R genes alongside 10 additional metabolic pathways, mapping 150+ insights about your peptide-hormone biology. These genetic markers correlate with semaglutide dose requirements, expected weight loss magnitude, and risk of certain side effects, enabling truly personalized protocol selection.

Related Reading

• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Weight Loss Drugs Like Ozempic
• Ozempic Weight Loss Before And After Pictures

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.